In COSMIC-313 trial presented by Dr. Toni Choueiri, #cabozantinib (C) in combination with #nivolumab (N) and #ipilimumab (I) improved PFS...

In the phase III, DATA study that was presented by Tjan-Heijnen el al, #extended_adjuvant endocrine therapy failed to improve the...

In the Chinese phase III, DAWNA-2 study presented by Xu el al, the addition of the CDK 4/6 inhibitor #Dalbiciclib...

In DESTINY-Lung02 trial Presented by Dr. Koichi Goto, Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg and 6.4 mg/kg demonstrated clinically meaningful activity...

In phase II ECOG-ACRIN E2211 trial, the addition of Capecitabine to Temozolomide significantly improved the progression-free survival (PFS) in patients...

In a study published in the Journal of clinical oncology, Oral #SERD, #Elacestrant significantly improved PFS compared to standard of...

In the prospective, randomized ENGOT/GCIG study by AGO s, GINECO, NSGO study groups, standard duration of #bevacizumab (15 months) treatment...

In the international phase III, EURO EWING 2012 trial, published in the Lancet, standard U.S. chemotherapy regimen improved the clinical...

In the phase III, GIM-2 study that was presented by Del Mastro el al, #dose_dense chemotherapy significantly improved DFS and...

In a retrospective analysis of the GOG-0218 trial, a modelled CA-125 ELIMination rate constant K (#KELIM) could identify patients who...